Insulet Corporation (PODD) Earnings Call Transcripts

Insulet Corporation's Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, Insulet Corporation reported total revenue of $802 million, reflecting a 23.5% increase year-over-year. Adjusted earnings per share (EPS) rose 41.5% to $1.36, showcasing strong profitability despite challenges in the Type 2 diabetes market. Management has adjusted its full-year revenue growth guidance to 20%-22% due to lower-than-expected retention rates among Type 2 customers, while raising the international growth outlook to 30%-32%.

Reported metrics

Guidance from management

Insulet expects full-year revenue growth of 20% to 22% and U.S. Omnipod growth of 17% to 19%, while raising international growth expectations to 30% to 32%. They are also cautious about the retention trends observed in the Type 2 market.

What management said

Sure. And Travis, just a couple of things. One, the range we provided is relatively wide. And the 9% is the bottom of the range, but the top of that range is 14%. So the midpoint is 12%. And it does contemplate the impact of the new product launches as well as the full benefit of our sales force expansion, which will accrue into 2027. So we believe, again, it's a prudent approach, as Ashley said. And we'll provide ...

Yes. And Jeff, just specifically to address your question about the Blues, we are not taking any positions that would result in exclusionary positions in access. So that was not something that was initiated by us, and we don't believe in that. So I just want to specifically address your question.

What analysts pressed on

Analysts expressed concerns regarding the retention rates among Type 2 customers and the potential impact of competition in 2027. Questions were raised about how management plans to address these challenges and whether the current guidance adequately reflects the competitive landscape.

Main topics on the call

• Revenue Growth — Insulet achieved a total revenue growth of 23% year-over-year on a constant currency basis, driven by strong demand for Omnipod in both U.S. and international markets. Management stated, "We saw strong demand for Omnipod...
• Type 2 Market Challenges — Management acknowledged challenges in the Type 2 market, particularly in customer retention and utilization during the first 90 days of therapy. CEO Ashley McEvoy stated, "We should have understood some of these Type 2 t...
• Adjusted Operating Margin Expansion — The adjusted operating margin increased by 140 basis points year-over-year to 19.3%, supported by manufacturing productivity and disciplined expense management. Flavia Pease noted, "Our ability to continue expanding marg...
• Guidance Update — Management updated its full-year revenue growth outlook to 20%-22%, reflecting revised assumptions about Type 2 customer retention. They also raised the international revenue growth outlook to 30%-32%, indicating strong ...

Read the full Insulet Corporation transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 89 Insulet Corporation earnings call transcripts on record, spanning January 14, 2020 to August 5, 2026. Based on this history, Insulet Corporation reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PODD

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

89

First call

January 14, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly